KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Assets (2016 - 2025)

Gsk (GSK) has 4 years of Non-Current Assets data on record, last reported at -$25.2 billion in Q4 2021.

  • For Q4 2021, Non-Current Assets changed N/A year-over-year to -$25.2 billion; the TTM value through Dec 2018 reached $44.3 billion, down 17.56%, while the annual FY2021 figure was -$25.7 billion, N/A changed from the prior year.
  • Non-Current Assets reached -$25.2 billion in Q4 2021 per GSK's latest filing, down from $44.3 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $53.7 billion in Q4 2017 and bottomed at -$25.2 billion in Q4 2021.
  • Average Non-Current Assets over 3 years is $24.3 billion, with a median of $44.3 billion recorded in 2018.
  • Peak YoY movement for Non-Current Assets: grew 19.74% in 2017, then fell 17.56% in 2018.
  • A 3-year view of Non-Current Assets shows it stood at $53.7 billion in 2017, then decreased by 17.56% to $44.3 billion in 2018, then crashed by 156.83% to -$25.2 billion in 2021.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were -$25.2 billion in Q4 2021, $44.3 billion in Q4 2018, and $53.7 billion in Q4 2017.